Eyfjörd J E, Thorlacius S
Molecular and Cell Biology Laboratory, Icelandic Cancer Society, Reykjavik.
Pharmacogenetics. 1992 Dec;2(6):309-16. doi: 10.1097/00008571-199212000-00010.
We have examined breast tumour samples from 109 unselected breast cancer patients for genetic changes on chromosomes 13 and 17. We have looked for allelic losses, firstly, at the retinoblastoma locus, RB1, on chromosome 13q, and secondly, on both arms of chromosome 17. We have also studied the same samples for amplification of the erbB2 oncogene. We searched for mutations in four well conserved areas of the p53 gene using constant denaturant gradient electrophoresis (CDGE). Allelic loss or rearrangement was detected in a large proportion of the tumours, affecting 37-51% of cases with different probes. The areas most frequently affected were 17p13.1 and 17p13.3. Point mutations and small deletions in the p53 gene on 17p13.1 were detected in 16% of the tumours. The data on genetic changes were then analyzed for three different correlations: 1) co-operation between different lesions, 2) association with family history of breast cancer, 3) correlation with clinical factors and prognosis. There was association between losses at the retinoblastoma locus and losses on 17p and 17q. We also found an association between p53 mutations and amplification of the erbB2 oncogene. Relatives of patients having deletions at the retinoblastoma locus and/or sites on chromosome 17 in the tumours have a significantly increased relative risk of developing breast cancer. No such correlation is found for p53 mutations or erbB2 amplification. No p53 germline mutations were detected. P53 mutations do, however, appear to be a strong indication of poor prognosis in this population.
我们检测了109例未经挑选的乳腺癌患者的乳腺肿瘤样本,以查找13号和17号染色体上的基因变化。我们首先在13号染色体长臂的视网膜母细胞瘤基因座RB1处寻找等位基因缺失,其次在17号染色体的两条臂上寻找。我们还研究了相同样本中erbB2癌基因的扩增情况。我们使用恒定变性剂梯度电泳(CDGE)在p53基因的四个高度保守区域中寻找突变。在大部分肿瘤中检测到等位基因缺失或重排,不同探针检测到的病例比例为37% - 51%。受影响最频繁的区域是17p13.1和17p13.3。在16%的肿瘤中检测到17p13.1上p53基因的点突变和小缺失。然后对基因变化数据进行了三种不同的相关性分析:1)不同病变之间的协同作用;2)与乳腺癌家族史的关联;3)与临床因素和预后的相关性。视网膜母细胞瘤基因座处的缺失与17p和17q上的缺失之间存在关联。我们还发现p53突变与erbB2癌基因扩增之间存在关联。肿瘤中视网膜母细胞瘤基因座和/或17号染色体上位点有缺失的患者亲属患乳腺癌的相对风险显著增加。未发现p53突变或erbB2扩增与上述情况有此类相关性。未检测到p53种系突变。然而,p53突变似乎是该人群预后不良的一个强烈指标。